Advancing foundational research from UCLA and Migal – Galilee Research Institute, ImmPact is working on T-cell therapies for liquid and solid cancers.
ImmPact Bio, a US-based developer of cancer treatments based on research at University of California, Los Angeles (UCLA) and Migal – Galilee Research Institute, picked up $111m in a series B round yesterday.
VenBio Partners, Foresite Capital and Decheng Capital led the round, in which pharmaceutical firms Bukwang Pharmaceutical and Novartis – the latter through its Novartis Venture Fund – also took part.
Additional investors included Surveyor Capital, OrbiMed and RM Global Partners (RMGP).
ImmPact Bio is working on chimeric…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
